Medicare’s decision to reimburse more of the cost of CAR-T therapies to hospitals for expensive new cancer treatments helps a little, hospital officials say, but doesn’t go nearly far enough. Joseph Alvarnas, an oncologist at the City of Hope Comprehensive Cancer Center, tells the Washington Post (in a response the newspaper described as “muted”) that “for now, this should probably be viewed as a step forward, but an incremental (rather than decisive) one.”

Continue reading on Managed Care.